Daunorubicin/cytarabine

From WikiProjectMed
Jump to navigation Jump to search
Daunorubicin/cytarabine
Cytarabin.svg
Cytarabine
Daunorubicin2DACS.svg
daunorubicin
Combination of
CytarabineAntimetabolite
daunorubicinAnthracycline
Names
Trade namesVyxeos
Clinical data
Pregnancy
category
  • US: N (Not classified yet)
Routes of
use
Intravenous
External links
AHFS/Drugs.comMonograph
US NLMDaunorubicin/cytarabine
Legal
License data
Legal status

Liposomal daunorubicin/Cytarabine is a combination medicine used to treat acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).[1][2]

It liposomal bound cytarabine and daunorubicin that delivers the two medications in a 5:1 molar ratio.


References

  1. "Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 2019-03-19.
  2. "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Retrieved 2018-12-30.

External links

Identifiers: